Point-of-care immunoassay for diagnosis of histoplasmosis in HIV/AIDS

用于诊断 HIV/AIDS 组织胞浆菌病的即时免疫分析

基本信息

  • 批准号:
    8306652
  • 负责人:
  • 金额:
    $ 28.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-25 至 2013-12-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Progressive disseminated histoplasmosis is a common and life-threatening fungal infection among patients with HIV/AIDS in the United States and Latin America. Incidence rates in HIV/AIDS can be >20%, with mortality rates >30% in resource-limited countries where the fungus, Histoplasma capsulatum, is endemic. Early diagnosis and treatment are essential to reducing this high mortality rate. Diagnosis currently depends on culture or histopathology. These methods have low sensitivity, are time consuming, are expensive, and require trained personnel. An alternative approach is an immunoassay to detect H. capsulatum polysaccharide in serum or urine. The target antigen is believed to be a cell wall galactomannan. Studies to date have found a high sensitivity for such assays. However, immunoassay for Histoplasma antigen i) is currently available only in ELISA format through use of a reference laboratory, ii) is not commercially available for distribution in resource-limited countries, iii) is dependent on the use of polyclonal rabbit antibodies (pAbs), and iv) is not amenable to point-of-care (POC) use. Our overall hypothesis is that an immunoassay for POC diagnosis of disseminated histoplasmosis in HIV/AIDS can be constructed with high-affinity monoclonal antibodies (mAbs) that target the polysaccharide antigen of H. capsulatum that is shed into serum and urine during infection. A corollary to this hypothesis is that the use of appropriate pairs of mAbs for assay construction will enable targeting of common and unique H. capsulatum epitopes, providing a control over assay specificity that is not possible with pAbs. The first Specific Aim is to produce polysaccharide antigens suitable for screening of hybridomas and evaluation of mAb specificity. The second Specific Aim is to produce a library of mAbs reactive with the spectrum of epitopes found on the Histoplasma polysaccharide antigen that is shed into serum and urine. If the goals of this Phase I are achieved, Phase II will use mAbs from Phase I to construct and evaluate an immunoassay in POC format. Our preferred assay platform would be the lateral flow immunochromatographic (dipstick) assay. If successful, this translational research project could dramatically decrease mortality from histoplasmosis through earlier diagnosis and treatment. Importantly, this can be done at the low cost needed in resource-limited countries.
描述(由申请人提供):进行性播散性组织胞浆菌病是美国和拉丁美洲HIV/AIDS患者中常见的危及生命的真菌感染。艾滋病毒/艾滋病的发病率可能> 20%,在资源有限的国家,组织胞浆菌是地方病,死亡率>30%。早期诊断和治疗对于降低这一高死亡率至关重要。诊断目前依赖于文化或组织病理学。这些方法灵敏度低,耗时,昂贵,并且需要训练有素的人员。另一种方法是免疫测定来检测H。血清或尿液中的荚膜多糖。靶抗原被认为是细胞壁半乳甘露聚糖。迄今为止的研究已经发现这种测定的高灵敏度。然而,组织胞浆菌抗原的免疫测定i)目前仅通过使用参考实验室以ELISA形式提供,ii)尚未在资源有限的国家进行商业分销,iii)取决于多克隆兔抗体(pAbs)的使用,和iv)不适合护理点(POC)使用。我们的总体假设是,可以用靶向H的多糖抗原的高亲和力单克隆抗体(mAb)构建用于HIV/AIDS中播散性组织胞浆菌病POC诊断的免疫测定法。在感染过程中脱落到血清和尿液中的包囊。该假设的推论是,使用适当的mAb对进行测定构建将能够靶向常见和独特的H。荚膜抗原表位,提供了对pAb不可能的测定特异性的控制。第一个具体目标是生产适用于杂交瘤筛选和mAb特异性评价的多糖抗原。第二个具体目标是产生与在脱落到血清和尿液中的组织胞浆菌多糖抗原上发现的表位谱反应的mAb文库。如果实现了第一阶段的目标,第二阶段将使用第一阶段的mAb构建和评价POC形式的免疫测定。我们优选的测定平台是侧流免疫层析(试纸)测定。如果成功,这项转化研究项目可以通过早期诊断和治疗大大降低组织胞浆菌病的死亡率。重要的是,这可以在资源有限的国家以所需的低成本完成。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SEAN BAUMAN其他文献

SEAN BAUMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SEAN BAUMAN', 18)}}的其他基金

Rabbit InMAD Discovery of Novel Biomarkers for POC Tuberculosis Diagnostic Assay
Rabbit InMAD 发现用于 POC 结核病诊断分析的新型生物标志物
  • 批准号:
    8837566
  • 财政年份:
    2014
  • 资助金额:
    $ 28.9万
  • 项目类别:
Rabbit InMAD Discovery of Novel Biomarkers for POC Tuberculosis Diagnostic Assay
Rabbit InMAD 发现用于 POC 结核病诊断分析的新型生物标志物
  • 批准号:
    8603728
  • 财政年份:
    2014
  • 资助金额:
    $ 28.9万
  • 项目类别:
Immunoassay for diagnosis of invasive fungal disease
用于诊断侵袭性真菌病的免疫分析
  • 批准号:
    8521621
  • 财政年份:
    2013
  • 资助金额:
    $ 28.9万
  • 项目类别:
Antigen Immunoassay for Diagnosis of Coccidioidomycosis
抗原免疫分析诊断球孢子菌病
  • 批准号:
    8392843
  • 财政年份:
    2012
  • 资助金额:
    $ 28.9万
  • 项目类别:
Antigen Immunoassay for Diagnosis of Coccidioidomycosis
抗原免疫分析诊断球孢子菌病
  • 批准号:
    8502239
  • 财政年份:
    2012
  • 资助金额:
    $ 28.9万
  • 项目类别:
Lateral Flow Assay for Diagnosis of Histoplasmosis
侧流层析检测用于诊断组织胞浆菌病
  • 批准号:
    9047228
  • 财政年份:
    2011
  • 资助金额:
    $ 28.9万
  • 项目类别:
Point-of-care immunoassay for diagnosis of histoplasmosis in HIV/AIDS
用于诊断 HIV/AIDS 组织胞浆菌病的即时免疫分析
  • 批准号:
    8209657
  • 财政年份:
    2011
  • 资助金额:
    $ 28.9万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 28.9万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 28.9万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 28.9万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 28.9万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 28.9万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 28.9万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 28.9万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 28.9万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 28.9万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 28.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了